Canntab Therapeutics Financials
| CTABF Stock | USD 0.0001 0.00 0.00% |
Canntab |
Understanding current and past Canntab Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Canntab Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Canntab Therapeutics' assets may result in an increase in income on the income statement.
Canntab Therapeutics Stock Summary
Canntab Therapeutics competes with Bionoid Pharma, HLS Therapeutics, Crescita Therapeutics, Centr Brands Corp, and Avicanna. Canntab Therapeutics Limited, a phytopharmaceutical company, engages in the research and development of advanced pharmaceutical grade formulations of cannabinoids in Canada. Canntab Therapeutics Limited is headquartered in Markham, Canada. Canntab Therapeutics is traded on OTC Exchange in the United States.| Instrument | USA Pink Sheet View All |
| Exchange | PINK Exchange |
| Business Address | 223 Riviera Drive, |
| Sector | Healthcare |
| Industry | Drug Manufacturers—Specialty & Generic |
| Benchmark | Dow Jones Industrial |
| Website | canntab.ca |
| Phone | 289 301 3812 |
| Currency | USD - US Dollar |
Canntab Therapeutics Key Financial Ratios
There are many critical financial ratios that Canntab Therapeutics' investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Canntab Therapeutics reports annually and quarterly.| Return On Equity | -6.02 | |||
| Return On Asset | -0.82 | |||
| Beta | 0.9 | |||
| Z Score | 3.6 |
Canntab Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Canntab Therapeutics's current stock value. Our valuation model uses many indicators to compare Canntab Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Canntab Therapeutics competition to find correlations between indicators driving Canntab Therapeutics's intrinsic value. More Info.Canntab Therapeutics Limited is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Canntab Therapeutics' earnings, one of the primary drivers of an investment's value.Canntab Therapeutics Systematic Risk
Canntab Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Canntab Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Beta measures systematic risk based on how returns on Canntab Therapeutics correlated with the market. If Beta is less than 0 Canntab Therapeutics generally moves in the opposite direction as compared to the market. If Canntab Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Canntab Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Canntab Therapeutics is generally in the same direction as the market. If Beta > 1 Canntab Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Canntab Therapeutics November 27, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Canntab Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Canntab Therapeutics Limited. We use our internally-developed statistical techniques to arrive at the intrinsic value of Canntab Therapeutics Limited based on widely used predictive technical indicators. In general, we focus on analyzing Canntab Pink Sheet price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Canntab Therapeutics's daily price indicators and compare them against related drivers.
| Information Ratio | (0.13) | |||
| Maximum Drawdown | 95.0 |
Complementary Tools for Canntab Pink Sheet analysis
When running Canntab Therapeutics' price analysis, check to measure Canntab Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Canntab Therapeutics is operating at the current time. Most of Canntab Therapeutics' value examination focuses on studying past and present price action to predict the probability of Canntab Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Canntab Therapeutics' price. Additionally, you may evaluate how the addition of Canntab Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |